help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Merciris, D.
Right arrow Articles by Geoffroy, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Merciris, D.
Right arrow Articles by Geoffroy, V.
(American Journal of Pathology. 2007;170:1676-1685.)
© 2007 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2007.061069

Overexpression of the Transcriptional Factor Runx2 in Osteoblasts Abolishes the Anabolic Effect of Parathyroid Hormone in Vivo

Didier Merciris*, Caroline Marty*, Corinne Collet{dagger}, Marie-Christine de Vernejoul* and Valerie Geoffroy*

From INSERM U606,* University Paris 7, and the Department of Biochemistry and Molecular Biology,{dagger} Hôpital Lariboisière, Paris, France

There is convincing evidence that Runx2 could be a regulator of the anabolic action of parathyroid hormone (PTH) in bone. We therefore decided to determine how Runx2 overexpression in osteoblasts affects the anabolic response to PTH. Transgenic osteoporotic female mice overexpressing Runx2 (TG) and their wild-type littermates (WT) were treated with PTH (100 µg/kg/day, 7 days a week) or with the vehicle for 6 weeks. Unexpectedly, Runx2 overexpression blunted the increase in the mineral density and volume of bone induced by intermittent PTH in WT mice. Our findings also indicate that PTH failed to increase bone formation in TG mice overexpressing Runx2. This abolition of the effect of PTH by Runx2 overexpression was attributable to a decrease in the differentiation of osteoblastic cells both in vivo and in vitro. Finally, we showed that less cAMP was induced by PTH and that there were fewer PTH binding sites in TG than WT osteoblasts. In conclusion, our findings demonstrate that in vivo a high level of Runx2 abolishes the anabolic effect of PTH, probably via a decrease in the sensitivity of TG osteoblasts to PTH, and that the level of expression of Runx2 is critical if PTH is to produce its anabolic effect on bone in vivo.




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
M. Biosse-Duplan, B. Baroukh, M. Dy, M.-C. de Vernejoul, and J.-L. Saffar
Histamine Promotes Osteoclastogenesis through the Differential Expression of Histamine Receptors on Osteoclasts and Osteoblasts
Am. J. Pathol., April 1, 2009; 174(4): 1426 - 1434.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
N. Samee, V. Geoffroy, C. Marty, C. Schiltz, M. Vieux-Rochas, G. Levi, and M.-C. de Vernejoul
Dlx5, a Positive Regulator of Osteoblastogenesis, is Essential for Osteoblast-Osteoclast Coupling
Am. J. Pathol., September 1, 2008; 173(3): 773 - 780.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
C. Collet, C. Schiltz, V. Geoffroy, L. Maroteaux, J.-M. Launay, and M.-C. de Vernejoul
The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation
FASEB J, February 1, 2008; 22(2): 418 - 427.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society for Investigative Pathology.